BioSpace13h
FDA Action Alert: Amgen, Aldeyra and Argenx
In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.
Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy?
We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...
Optimist3d
Learning to Walk Again: McCabe-Gossett continues journey back from neurological disorder
Jasmine McCabe-Gossett began noticing mild neuropathy in her hands and feet. It quickly progressed to “one of the most ...
Takeda Canada says Health Canada expands marketing authorization for HyQvia
Canada announced that Health Canada has expanded the marketing authorization for HyQvia for chronic inflammatory demyelinating polyneuropathy as maintenance therapy after stabilization with ...
Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)
Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...
Argenx: The Magic May Be Already Priced In
Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...